Mabion: Surges on COVID-19 vaccine deal with Novavax

Mabion SA

03/03/2021 08:35

** Shares in Poland's drug developer Mabion  MABP.WA  surge
45.2% after the company clinched a framework deal with the U.S.
vaccine developer Novavax  NVAX.O  under its COVID-19 vaccine
programme
    ** Under the deal, the parties' intention is to possibly
include Mabion's production plant in Novavax's commercial
production chain of an active ingredient for Novavax vaccine
 urn:newsml:reuters.com:*:nFWN2L0158
    ** Mabion also said it had secured a financing deal with
Polish Development Fund for up to 40 million zlotys  ($10.67
million)  urn:newsml:reuters.com:*:nFWN2L01AJ
    ** Wednesday's gains added about 194.0 million zlotys 
($51.7 million) to the company's market cap, bringing it to
around 623.1 million zlotys
    ** About 371.8 thousand shares traded so far, i.e. around
501.2% of their 30-day moving average, with shares on track for
their best day ever

($1 = 3.7505 zlotys)

 ((karl.badohal@thomsonreuters.com))